Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases | Business Wire

Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases | Business Wire: Alteogen and Lynkogen enter into an exclusive option agreement to develop proprietary fusion proteins for the treatment of NASH and metabolic diseases